The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma

Histopathology

Volumn 53, Issue 1, 2008, Pages 30-38

  Richardsen, E ^a   Uglehus, R D ^a   Due, J ^a,b   Busch, C ^a,c   Busund, L T R ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CD3; CD68; CSF 1 receptor; Digital video analysis; M CSF; Macrophages; Metastases; Prognosis; Prostatic cancer; T lymphocytes

Indexed keywords

CD3 ANTIGEN; CD68 ANTIGEN; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER PATIENT; CANCER TISSUE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LYMPH NODE METASTASIS; MACROPHAGE; MALE; METASTASIS; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; T LYMPHOCYTE; VIDEORECORDING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MICROSCOPY, VIDEO; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 45549093317     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03058.x     Document Type: Article

References (37)

1. Chackal-Roy M, Niemeyer C, Moore M et al. Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J. Clin. Invest. 1998 84 43 50.
2. Nelson WG, De Marzo AM, Isaacs W. Prostate cancer. N. Engl. J. Med. 2003 24 366 381.
3. Ide H, Segligson DB, Memarzaseh A et al. Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc. Natl Acad. Sci. U.S.A. 2002 29 14404 14409.
4. Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br. J. Cancer 2004 90 2053 2058.
5. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002 420 860 867.
6. Elgert KD, Alleva DG, Mullins DW. Tumour-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 1998 64 275 288.
7. Pollard JW. Tumour-educated macrophages promote tumour progression and metastases. Nat. Rev. Cancer 2004 4 71 78.
8. Condeelis J, Pollard JW. Macrophages: obligate partners for tumour cell migration, invasion, and metastases. Cell 2006 124 263 266.
9. Leek RD, Lewis CE, Whitehouse R et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1999 56 4625 4629.
10. Lewis CE, Pollard JW. Distinct role of macrophages in different tumour microenvironments. Cancer Res. 2006 66 605 612.
11. Chambers SK, Kacinski BM, Ivins CM et al. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with protective effect of stromal CDF-1. Clin. Cancer Res. 1997 3 999 1007.
12. Lin EY, Gouon-Evans V, Nguyen AV et al. The macrophage growth factor csf-1 in mammary gland development and tumour progression. J. Mammary Gland Biol. Neoplasia 2002 7 147 162.
13. Savarese DMF, Valinski H, Qesenberry P et al. Expression of colony-stimulating factors and their receptors in human prostate carcinoma cell lines. Prostate 1998 34 80 91.
14. Lissbrant IF, Stattin P, Wikstrøm P et al. Tumour associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int. J. Oncol. 2002 17 445 451.
15. McDermott RS, Deneux L, Mosseri V et al. Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur. Cytokine Netw. 2002 13 121 127.
16. Eble JN, Sauter G, Epstein JI et al. World Health Organization classification of tumours. Pathology and genetics. Tumours of the urinary system and male genital organs. Lyon:IARC, 2004.
17. Ichim CV. Revisiting immunosurveillance immunostimulation: implications for cancer immunotherapy. J. Transl. Med. 2005 3 1 13.
18. Lin EY, Nguyen AV, Russel RG et al. Colony-stimulating factor 1 promotes progression of mammary tumours to malignancy. J. Exp. Med. 2001 193 727 239.
19. Leek RD, Harris AL. Tumour-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasia 2002 7 177 189.
20. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity inflammation. Curr. Opin. Immunol. 2006 18 39 48.
21. Crowther M, Brown NJ, Bishop ET et al. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumours. J. Leukoc. Biol. 2001 70 478 490.
22. Goswami S, Sahai E, Wyckoff JB et al. Macrophage promotes the invasion of breast carcinoma cells via a colony factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005 65 5278 5283.
23. Lewis C, Murdoch C. Macrophage responses to hypoxia. Implications for tumour progression and anti-cancer therapies. Am. J. Pathol. 2005 3 627 635.
24. Wyckoff J, Wang W, Lin EY et al. A paracrine loop between tumour cells and macrophages is required for tumour cell migration in mammary tumours. Cancer Res. 2004 64 7022 7029.
25. Kacinski BM. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol. Reprod. Dev. 1997 46 71 74.
26. Mocellin S, Wang E, Marincola FM. Cytokine and immune response in tumour microenvironment. J. Immunother. 2001 24 392 407.
27. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new cancer therapies. J. Pathol. 2002 196 254 265.
28. Shimura S, Yang G, Ebara S et al. Reduced infiltration of tumour-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000 60 5857 5861.
29. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopatology 1999 19 403 410.
30. Irani JR, Goujon JM, Ragni E et al. The Pathologist Multi Center Study Group. High grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urology 1999 54 467 472.
31. MArdle PA, Canna K, McMillan DC et al. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. BMJ 2004 91 541 543.
32. Mercader M, Bodner BK, Moser MT et al. T-cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl Acad. Sci. U.S.A. 2001 98 14565 14570.
33. Vesalainen S, Lipponen P, Talja M et al. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostate carcinoma. Eur. J. Cancer 1994 30A 1797 1803.
34. De Boer WI, Hiemstra PS, Sont JK et al. Image analysis and quantification in lung tissue. Clin. Exp. Allergy 2001 31 504 508.
35. Faul JL, Demers EA, Burke CM et al. The reproducibility of repeated measures of airway inflammation in stable atopic asthma. Am. J. Respir. Crit. Care Med. 1999 160 1457 1461.
36. Sulivan P, Stephens D, Ansari T et al. Variation in the measurements of basement membrane thickness and inflammatory cell number in bronchial biopsies. Eur. Respir. J. 1998 12 811 815.
37. Benzinou A, Hojeij Y, Roudot AC. Digital image analysis of haematopoietic clusters. Comput. Methods Programs Biomed. 2005 77 121 127.